Glucanase

Other Names

(1→3)-β-glucan 3-glucanohydrolase1,3-(1,3;1,4)-beta-D-glucan 3(4) glucanohydrolase1,3-1,4-β-D-glucan 4-glucanohydrolase1,3-β-D-glucan 3-glucanohydrolase1,3-β-D-glucan glucanohydrolase1,4-(1,3;1,4)-β-D-glucan 4-glucanohydrolase3-beta-D-glucan glucanohydrolase4-β-D-glucan 4-glucanohydrolaseavicelasebeta-glucanasecallasecarboxymethyl cellulasecellobiohydrolasecelludextrinasecellulaseCMCaseEC 3.2.1.39EC 3.2.1.4EC 3.2.1.6EC 3.2.1.73endo-1,3(4)-beta-glucanaseendo-1,3-beta-glucanaseendo-1,3-β-D-glucanaseendo-1,3-β-glucanaseendo-1,3-β-glucosidaseendo-1,4-β-D-glucanaseendo-β-1,3-1,4 glucanaseendo-β-1,4-glucanaseendoglucanaseexoglucanaseGlucan endo-1,3-beta-D-glucosidasekitalaselaminaranaselaminarinaselichenaselicheninasemixed linkage β-glucanaseoligo-1,3-glucosidaseβ-1,3-glucanaseβ-1,4-endoglucan hydrolaseβ-1,4-glucanaseβ-glucanase

Synopsis

Glucanase (Beta-Glucanase): A Comprehensive Reference

1. Identity, Nomenclature, and Classification

Glucanase — most specifically referred to as beta-glucanase (β-glucanase) in the scientific and regulatory literature — is a collective term for a family of hydrolytic enzymes that catalyze the cleavage of glycosidic bonds within glucan polysaccharides. Glucanase is an enzyme that breaks down glucans, a type of complex carbohydrate found in the cell walls of grains, fungi, and some bacteria. In dietary supplement and food-ingredient contexts, the term "glucanase" is used interchangeably with "beta-glucanase," though the two terms technically refer to slightly different scopes.

The Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (IUBMB) and the Enzyme Commission (EC) classify these enzymes according to their catalytic action patterns against specified substrates (endo- or exo-), the type of linkages they hydrolyze (β-1,3), the substrate hydrolyzed (β-glucan), and the type of reaction catalyzed (hydrolase).

Several distinct Enzyme Commission numbers are assigned to different members of this enzyme family:

EC 3.2.1.58: exo-β-1,3-glucanases, which cleave D-glucose from the nonreducing end of the glucan molecule; and EC 3.2.1.39: endo-β-1,3-glucanases, which require at least two β-1,3-bound glucose residues adjacent to the cleavage site.
EC 3.2.1.73: beta-(1,3)(1,4)-glucanase, a polypeptide capable of catalysing the hydrolysis of 1,4-beta-D-glucosidic linkages in beta-D-glucans containing 1,3- and 1,4-bonds.
The systematic name for the endo-1,3(4)-beta-glucanase is 1,3-(1→3;1→4)-β-D-glucan 3(4)-glucanohydrolase. Other names include endo-1,3-β-D-glucanase; laminarinase; and related designations.

This enzyme may also be referred to as licheninase, 1,3-1,4-beta-D-glucan 4-glucanohydrolase, beta-glucanase, endo-beta-1,3-1,4 glucanase, lichenase, or mixed linkage beta-glucanase. Alternative names include endo-1,3-beta-glucanase, laminarinase, and 1,3-(1,3;1,4)-beta-D-glucan 3(4) glucanohydrolase. Substrates include laminarin, lichenin, and cereal beta-D-glucans.

The broader classification system for these enzymes places them within glycoside hydrolase (GH) families. The accumulation of data about the structure of glycoside hydrolases has led to the elaboration of a new system for classification based on the homology of amino acid sequences, their 3D structures, and mechanisms of action. At the present time, there are over 170 different families present in the online CAZy database.

1.1 Key Structural Distinction: Plant vs. Fungal Glucans

The structure of the plant glucan differs from that of the fungal glucan: the former is composed of β-1,3–1,4 structures which are hydrolyzed by the β-1,4 glucanase, while the latter — the fungal glucan — presents a β-1,3 backbone being hydrolyzed by the β-1,3 glucanase. This structural distinction is significant for both the enzyme's specificity and its application as a supplement.

2. Natural Sources and Production Organisms

Glucanase enzymes are not synthesized by the human body in quantities sufficient to efficiently degrade dietary beta-glucans. The human digestive system does not naturally produce enough beta-glucanase to efficiently digest these fibers. Commercial and supplemental preparations are therefore derived from microbial fermentation.

Enzymes with β-glucanase activity are produced through fermentation with a variety of fungi and bacteria (Aspergillus, Trichoderma, Penicillium, Bacillus) and, as a result, have different substrate and product specificities. A more expansive list of producing organisms includes:

Rhizomucor miehei, Sclerotium rolfsii, Penicillium echinulatum, Trichoderma viride, Fusarium oxysporum, and Bacillus subtilis, which produce endo- and exo-glucanase enzymes when grown on biomass sources.
Commercial β-glucanase preparations used in the brewing industry are produced by Bacillus amyloliquefaciens. Fungal β-glucanases are also produced by fungi of the Aspergillus group, and are often formed as a side activity in pectinase preparations.
Other beta-glucanases in current use include those from Bacillus amyloliquefaciens, Aspergillus niger, Trichoderma reesei, Talaromyces emersonii, and Humicola insolens.
Wine glucanases (β-1,3–1,6 glucanase) are produced by applying Trichoderma harzianum.

Glucanase activity also occurs naturally in germinating cereal grains. During the malting stage, β-glucanase enzymes are produced; these facilitate the breakdown of the endosperm cell walls and the release of starch and proteases. Grains such as oats, barley, wheat, and rye are natural repositories of beta-glucan substrates on which endogenous plant glucanases act during germination.

2.1 Common Forms and Preparations

Glucanase is available in several forms as a supplement or food additive:

Capsules and powder: Beta-glucanase supplements are typically available in capsule or powder form and can be taken orally. They may be used to help the body break down beta-glucans from sources such as oats, barley, and certain types of mushrooms.
Enzyme activity units: BGU (Beta Glucanase Unit) is an FCC measurement based on 15-minute hydrolysis of lichenin substrate at 40°C and pH 6.5. The FCC notation stands for Foods Chemical Codex, which is a division of USP (United States Pharmacopeia), and sets standards for ingredients. In the case of enzymes, FCC is a standard assay used to accurately determine the activity of enzymes.
Multi-enzyme blends: Partially or indigestible glucan-comprising protein is fully or partially degraded by glucanases (or cellulases), mannanases, xylanases, amylases, xanthanases, and/or glycosidases in combination with one another. These blended formulations are common in digestive enzyme supplements.
Fermentation-derived liquid and solid concentrates: Some commercial preparations contain beta-glucanase produced by the natural fermentation process of Trichoderma reesei, derived from vegetarian, non-GMO sources.

3. Historical and Traditional Use

The purified enzyme glucanase is a product of modern biotechnology and enzyme science, with no direct pre-modern history as an isolated ingredient. However, the natural glucanase activity present in fermented foods and germinating grains has been exploited across human history without the practitioners being aware of the underlying biochemistry.

3.1 Traditional Food and Medicinal Contexts

Although the purified enzyme itself is a modern development, remedies harnessing the natural glucanase activity from plants and fungi have been part of traditional medicine across various cultures. For centuries, healers utilized mushrooms, barley, and oats — not only for their nutritional value, but also for their ability to support digestion and immunity, effects now attributed in part to glucanase activity.

In particular, the fermentation of grains and medicinal fungi, common in Eastern herbal traditions, produced glucanase-rich preparations thought to alleviate digestive complaints and boost overall vitality.

Herbalists and traditional healers recognized the health benefits associated with beta-glucan-rich foods and would often combine these ingredients in tonics, teas, and poultices to bolster the body's natural defenses, especially during times of illness or recovery.

3.2 Industrial and Agricultural Origins

The use of beta-glucanase in nutritional products traces back historically to improvements in animal feed digestibility, particularly in poultry and swine nutrition. By hydrolyzing beta-glucans, beta-glucanase helps reduce gut viscosity and enhances nutrient absorption, leading to better growth performance in livestock.

The brewing industry has made use of glucanase activity for as long as grain has been malted. Malting, the process of germinating cereal grains for brewing purposes, is a crucial step in the production of beer, with roots dating back thousands of years. Beta-glucanases are particularly important in malting, with increased activity occurring during the malting process. The main representatives of the cytolytic acting enzyme group are the β-glucanases and xylanases. They are responsible for the degradation of cell walls and promote the degradation of beta-glucans, pentosans, and other structural substances during malting and mashing.

The use of exogenous glucanase preparations added directly to brewing processes is a more recent development. A range of exogenous enzymes — such as glucanases, acetolactate decarboxylase, and prolyl endopeptidase — are available for enhancement of the existing brewing process. In winemaking, specific glucanases have been developed to hydrolyze Botrytis and yeast glucans in order to improve clarification and filterability of wines.

With the advent of enzyme science, the specific role of beta-glucanase became clearer. The formulation of purified or semi-purified glucanase as a standalone dietary supplement is largely a phenomenon of the late 20th and early 21st centuries, growing out of the animal feed enzyme industry.

4. Key Constituents and Active Compounds

Glucanase preparations are themselves the active constituent — they are enzyme proteins, not small-molecule compounds. The health-relevant chemistry involves the enzyme's ability to act on its substrate, beta-glucan, to produce specific degradation products.

4.1 Substrate: Beta-Glucan

Beta-glucanase is an enzyme that catalyzes the breakdown of beta-glucans, complex polysaccharides found in the cell walls of cereals, yeast, and fungi. Beta-glucan is the most abundant type of dietary fiber in oats and barley. It consists of β-1,4-glucopyranosyl residues with interspersed β-1,3-linkages and has greater flexibility and solubility than arabinoxylan, with soluble forms contributing to the viscosity of aqueous extracts and doughs.

These polysaccharides, found in cereals, fungi, and yeast, are not digested by human enzymes but are fermented by gut bacteria, yielding various health benefits.

4.2 Molecular Mechanism of Action

Beta-glucanase targets beta-glucans by breaking the glycosidic bonds (the chemical links in carbohydrate chains) between glucose molecules. By doing so, beta-glucanase converts these large, hard-to-digest fibers into smaller sugars that the body can more easily handle and absorb.

At the molecular level, the mechanism is well characterized. The hydrolytic mechanism of β-glucanases, particularly those from Bacillus species such as Bacillus licheniformis, follows a double-displacement reaction. This involves two main steps: glycosylation and deglycosylation. During glycosylation, a catalytic nucleophile attacks the anomeric carbon of the substrate, forming a covalent enzyme-substrate intermediate. This is followed by deglycosylation, where a water molecule activated by a general acid-base attacks the intermediate, completing the hydrolysis and releasing the product.

In the case of Bacillus 1,3-1,4-β-glucanases, which are retaining endo-glycosidases of family 16 GH, the catalytic mechanism involves a catalytic triad. This triad consists of two glutamic acid residues (Glu134 and Glu138) and an aspartic acid residue (Asp136). Glu134 serves as the enzyme nucleophile, Glu138 acts as the general acid-base, and Asp136 assists in catalysis by participating in both glycosylation and deglycosylation steps.

Endo-1,3(4)-β-glucanases catalyse the hydrolysis of 1,3- or 1,4-β-glycosidic linkages in mixed-linked β-D-glucans, resulting in the generation of partially hydrolysed β-D-glucans.

4.3 Degradation Products and Their Properties

Depolymerized (1→3)(1→6)-β-D-glucans produced by β-1,3-D-glucanase effectively produce degraded products with biological and functional properties suitable as pharmaceuticals or as prebiotics in foods and beverages. The shorter oligosaccharide chains generated by glucanase activity retain some biological signaling activity, including potential prebiotic and immunomodulatory properties.

Regarding the relationship between glucanase activity and beta-glucan's health effects, there is a nuanced consideration: beta-glucans also have health benefits as dietary fiber, and hence high activity of β-glucanase is not always desirable. Whether glucanase action on beta-glucans enhances or diminishes their downstream health effects depends on the specific context, the molecular weight of the resulting fragments, and the site of hydrolysis in the gastrointestinal tract.

5. Scientific Evidence by Area of Use

It is essential to distinguish between (a) the scientific evidence relating to beta-glucan itself — for which substantial regulatory-grade clinical evidence exists — and (b) the evidence for exogenous glucanase supplementation specifically modifying health outcomes in humans, where the evidence remains considerably more limited and primarily derived from in vitro and animal studies. Where human studies exist for glucanase specifically, they are noted separately.

5.1 Digestive Function and Nutrient Absorption

Mechanism (established): By hydrolyzing beta-glucans, beta-glucanase helps reduce gut viscosity and enhances nutrient absorption. When added to food, the glucanase significantly improves the in vivo breakdown of glucan-containing material, such as plant cell walls, whereby a better utilization of the plant nutrients by the human or animal is achieved.

Human/clinical evidence: Direct human intervention studies examining exogenous glucanase as a standalone digestive supplement are sparse in the peer-reviewed literature. The evidence base is primarily drawn from: (1) studies of glucanase in food processing showing altered food properties, and (2) indirect evidence from oat drink studies. Oat drinks with added β-glucanase result in higher postprandial satiety and lower blood levels of glucose and insulin after consumption. This observation derives from food-science research rather than controlled clinical trials of the enzyme as a supplement per se.

Animal feed evidence: The production of short-chain fatty acids (SCFAs) was increased and the population of beneficial bacteria such as Lactobacillus spp. was positively influenced in pigs fed a high-quality barley-based diet. Evidence strength in this area is moderate-to-strong in animal models but has not been fully replicated in human clinical trials for the enzyme supplement specifically.

5.2 Blood Cholesterol and Cardiovascular Health

Evidence context: This is the area with the strongest clinical evidence — but the evidence pertains to intact beta-glucan fiber (not the glucanase enzyme itself). Glucanase is relevant here because it alters the molecular weight and viscosity of beta-glucan, which in turn can affect cholesterol outcomes.

Regulatory recognition of beta-glucan: The contribution of beta-glucans from oat and barley to the maintenance of normal blood cholesterol levels and their efficacy in the reduction of blood cholesterol levels at a dosage of 3 g per day was formally recognized by the European Food Safety Authority (EFSA) following specific applications and health claims authorized in the European Union (Commission Regulation (EU) 432/2012).

The food constituent barley beta-glucans is sufficiently characterised for this claim. Lowering blood LDL-cholesterol concentration is a beneficial physiological effect by decreasing the risk of coronary heart disease. A total of 16 references were identified as pertinent to the health claim, comprising three meta-analyses, 10 human intervention studies, two animal studies, and one mechanistic study.

Early analyses indicate that approximately 3 g of soluble fiber from oats reduced cholesterol by 0.13 mmol/L, whereas more recent analyses indicate a reduction in low-density lipoprotein (LDL-C) of approximately 0.27 mmol/L for a similar intake.

Relevance to glucanase: The viscosity of beta-glucan solutions is central to the cholesterol-lowering mechanism. The beneficial effect of cereal beta-glucan has been explained by the formation of a viscous solution in the small intestine and/or increased barrier function of the mucus layer, delaying the absorption of glucose and reducing the post-prandial glycemic response. Delayed absorption is also the established mechanistic explanation of the reduction in blood cholesterol and re-absorption of bile acids, reducing the risk of cardiovascular diseases. Because glucanase enzymatically degrades beta-glucan (reducing its molecular weight and viscosity), excessive glucanase activity in the gut could theoretically diminish these favorable effects.

5.3 Blood Glucose Regulation and Glycemic Response

Human clinical evidence for beta-glucan: In one randomized, double-blind, controlled study, 14 subjects ingested a breakfast with or without β-glucan from oats (5.2 g). Compared to control, β-glucan increased orocecal transit time and significantly decreased mean appetite score and postprandial plasma ghrelin, C-peptide, insulin, and glucose.

The EFSA-accepted claim for reduction in post-prandial glycemia relates to the consumption of 4 g beta-glucans per 30 g available carbohydrate. EFSA recommends that the glucose response is lowered when approximately 4 g β-glucan (per 30 g of available carbohydrates) from barley or oats, alone or per meal, is consumed.

A significant dose-response effect of low amounts of oat β-glucan on glycemic response has also been shown, with each gram of oat β-glucan reducing the area under the curve by 7%.

Glucanase-specific interaction: Beta-glucanase can be used in combination with other cell wall degrading enzymes to prepare cereal beta-glucans with different chain lengths for use in beverages. Oat drinks with added β-glucanase result in higher postprandial satiety and lower blood levels of glucose and insulin levels after consumption. This suggests that controlled enzymatic partial hydrolysis of oat beta-glucan — rather than complete degradation — may retain or even enhance glycemic benefits. Evidence is preliminary and derived from food-science contexts rather than clinical supplement trials.

5.4 Gut Microbiota and Prebiotic Effects

In vitro and in vivo evidence (not direct human glucanase supplementation trials): Beta-glucans contribute significantly to gut health by enhancing gut barrier integrity, modulating inflammation, and promoting the production of short-chain fatty acids (SCFAs) through fermentation by gut microbiota. The fermentation of beta-glucans by gut bacteria produces SCFAs such as acetate, propionate, and butyrate which support gut health. Butyrate serves as an energy source for colonocytes, protects against colorectal cancer, and exhibits anti-inflammatory effects. Acetate influences lipid metabolism and immune regulation, while propionate aids in cholesterol reduction and enhances gut barrier health.

Research has shown that beta-glucan cannot be hydrolyzed in saliva, gastric, or small intestinal conditions. Beta-glucan therefore reaches the large intestine, where it is degraded and metabolized by gut microbiota. Beta-glucan can modulate the structure and composition of gut microbiota by inhibiting the proliferation of harmful gut microbiota and promoting the growth of health-promoting gut microbiota.

With respect to microbiota diversity, a randomized study found that 32 subjects distributed into two groups who ingested daily foods with 3 g/day beta-glucan for 3 weeks showed no changes in fecal microbiota composition or diversity upon deep sequencing. This highlights the complexity and limitations of current evidence regarding beta-glucan's microbiota effects and illustrates that further study is needed. Further research is needed to explore the long-term effects of beta-glucan supplementation on gut microbiota, immune health, and chronic disease prevention.

5.5 Candida Biofilm Disruption and Antifungal Enhancement

This is an active area of in vitro and preliminary research concerning the direct enzymatic use of β-1,3-glucanase as an anti-biofilm agent. Evidence is currently limited to laboratory (in vitro) studies and animal models — no controlled human clinical trials of glucanase for antifungal purposes had been published at the time of writing.

Mechanism: The extracellular matrix of Candida biofilms is rich in β-1,3-glucans, which constitute the main barrier to the penetration of antifungal drugs.

In vitro evidence: Beta-1,3-glucan plays a role in Candida biofilm formation and survival of biofilm-forming Candida to stresses. Studies evaluated the antibiofilm activity of β-1,3-glucanase, which can degrade poly-β(1→3)-glucose of Candida albicans biofilms. In one study, biofilm was dispersed by 55.96%.

Beta-1,3-glucanase also detached mixed-species biofilm in microplate and on medical material surfaces. The enzyme had no effect on Candida planktonic growth or adhesion. However, further biofilm formation was inhibited with β-1,3-glucanase added 24 hours after biofilm initiation. Beta-1,3-glucanase markedly enhanced the antifungal susceptibility of amphotericin B.

These findings suggest that drug development targeting matrix β-1,3 glucan may potentiate the activity of currently available antifungal options. Evidence strength in this area is preliminary (in vitro only); translation to human clinical outcomes has not been established.

5.6 Immune Modulation

Indirect evidence via beta-glucan substrate: Various biological activities of beta-glucans have been reported such as anticancer, antidiabetic, anti-inflammatory, and immune-modulating effects. Clinical and animal studies have demonstrated that beta-glucans balance pro- and anti-inflammatory cytokines, supporting gut homeostasis and offering protection against chronic inflammation in conditions like inflammatory bowel disease.

Whether exogenous glucanase supplementation enhances immune outcomes — either by increasing the bioavailability of immunologically active glucan fragments or by assisting in biofilm clearance — is a question that remains unanswered at the level of human clinical trials. Clinical studies show that beta-glucans from oats, barley, mushrooms, and yeast improve symptoms of irritable bowel syndrome, reduce inflammation in inflammatory bowel disease, and support immune health in individuals prone to infections. Again, this evidence applies to the glucan substrate rather than to the supplemental enzyme.

5.7 Summary of Evidence Strength by Area

Beta-glucan's cardiovascular and glycemic benefits: Strong — supported by multiple human RCTs, meta-analyses, and formally accepted EFSA and FDA health claims.
Glucanase as a digestive enzyme supplement (human): Weak to preliminary — mechanistic plausibility is established, but controlled human clinical trials specifically examining exogenous glucanase supplementation as a digestive aid are lacking in the peer-reviewed literature.
Anti-Candida biofilm effects: Preliminary in vitro only — no human trials.
Gut microbiota modulation via glucanase: Indirect and preliminary — derived primarily from studies of beta-glucan itself, not the enzyme.

6. Body Systems and Health Areas Associated with Glucanase

Based on the available scientific evidence, glucanase is associated with the following body systems and health areas:

Gastrointestinal system: By hydrolyzing beta-glucans, beta-glucanase helps reduce gut viscosity and enhances nutrient absorption.
Cardiovascular system: Through modulation of beta-glucan molecular weight and viscosity, glucanase indirectly influences the substrate involved in established cholesterol-lowering mechanisms.
Immune system: Beta-glucans contribute significantly to gut health by enhancing gut barrier integrity, modulating inflammation, and promoting the production of SCFAs through fermentation by gut microbiota. Glucanase shapes the pool of beta-glucan fragments available for these interactions.
Metabolic/glycemic regulation: Glucanase influences the structural properties of ingested beta-glucans, affecting their interaction with glucose absorption in the small intestine.
Antifungal defense (in vitro context): Beta-1,3-glucan plays a role in Candida biofilm formation and survival of biofilm-forming Candida to stresses. Glucanase has demonstrated the capacity to disrupt such biofilms in laboratory models.

7. Dosage Forms and Reported Dosages

Because glucanase is an enzyme, it is quantified in activity units rather than mass units, which makes dose comparison across products and studies challenging.

Activity unit standard: BGU (Beta Glucanase Unit) is an FCC measurement based on 15-minute hydrolysis of lichenin substrate at 40°C and pH 6.5. This is the standard unit reported on dietary supplement labels in the United States.
Food-processing use level: Beta-glucanase from B. subtilis is used as an enzyme in the production of beer and potable alcohol at levels up to 37 milligrams total organic solids per kilogram (mg TOS/kg) of grist.
Brewing malt application: 50 mg/kg of commercial beta-glucanase from AB Enzymes is reported as sufficient to produce good quality malt.
Dietary exposure (European populations): Dietary exposure to the food enzyme total organic solids (TOS) was calculated to be up to 0.110 mg TOS/kg body weight per day in European populations based on EFSA food enzyme safety assessments — this represents incidental exposure from food processing applications, not supplement use.

No peer-reviewed human clinical trials establishing a specific therapeutic or optimal supplemental dosage of glucanase for health outcomes in humans were identified in the authoritative literature. Dosage guidance found on commercial supplement labels is not sourced from controlled clinical trial data and has not been reviewed here.

8. Safety Considerations

Glucanase has been subject to rigorous formal safety evaluation by two major regulatory bodies: the U.S. Food and Drug Administration (FDA) under the GRAS (Generally Recognized as Safe) framework, and the European Food Safety Authority (EFSA) under the EU Food Enzyme Regulation (EC) No. 1332/2008.

8.1 FDA GRAS Status

DuPont Industrial Biosciences first determined beta-glucanase from B. subtilis to be GRAS in 2012. The subject of this GRAS notice is beta-glucanase enzyme preparation produced by Bacillus subtilis expressing the gene encoding beta-glucanase from B. subtilis.

Toxicological studies (FDA-reviewed):

A 90-day acute oral toxicity study conducted using rats showed that consumption of beta-glucanase enzyme did not cause any treatment-related adverse effects up to the highest dose tested, i.e., 1000 mg TOS/kg body weight per day.
Tests conducted using bacterial cells showed that the beta-glucanase is not mutagenic at the highest dose tested, both in the presence and absence of metabolic activation. The enzyme is also not clastogenic based on results from in vitro chromosomal aberration tests.
Based on the highest dose tested in the 90-day study and the estimated dietary exposure from the intended use of beta-glucanase enzyme preparation, the margin of safety was calculated to be approximately 6400.
Based on the results of these safety studies and other information in published literature, the beta-glucanase enzyme preparation was considered safe for human consumption.

8.2 EFSA Safety Evaluations

EFSA's Panel on Food Contact Materials, Enzymes, and Processing Aids (CEP Panel) has conducted multiple independent safety evaluations of endo-1,3(4)-β-glucanase from various production organisms. Findings from several of these evaluations are consistent:

From Trichoderma reesei strain TG-M5-337: The Panel identified a no observed adverse effect level (NOAEL) at 1958 mg TOS/kg bw per day, the highest dose tested, with a resulting margin of exposure of at least 6573. A search for homology of the amino acid sequence to known allergens found no match. The Panel considered that a risk of allergic reactions upon dietary exposure cannot be excluded, but that the likelihood is low. The Panel concluded that this food enzyme does not give rise to safety concerns under the intended conditions of use.
From Talaromyces versatilis strain PF8: Genotoxicity tests did not indicate a safety concern. The systemic toxicity was assessed by means of a repeated dose 90-day oral toxicity study in rats. The Panel identified a NOAEL of 2229 mg TOS/kg bw per day, the highest dose tested, resulting in a margin of exposure of at least 20,264.
From Rasamsonia composticola strain 427-FS: The systemic toxicity was assessed by means of a repeated dose 90-day oral toxicity study in rats. The Panel identified a NOAEL of 866 mg TOS/kg bw per day, the highest dose tested, with a margin of exposure of at least 1,070. A search for the similarity of the amino acid sequence to known allergens found no match. The Panel considered that, under the intended conditions of use, the risk of allergic reactions by dietary exposure cannot be excluded, but the likelihood is low. The Panel concluded that this food enzyme does not give rise to safety concerns under the intended conditions of use.
Presence of viable production organism cells: In one notable exception, the Panel considered that the risk of allergic reactions could not be excluded but the likelihood was low; however, due to the presence of viable cells of the production strain in the food enzyme from Cellulosimicrobium funkei strain AE-TN, the Panel concluded that the food enzyme from that specific preparation could not be considered safe. This illustrates that safety assessment is product-specific and dependent on manufacturing controls that remove viable microbial cells.

8.3 Allergenicity

As a protein enzyme, glucanase carries a theoretical allergenicity potential. Across multiple EFSA evaluations, searches of glucanase amino acid sequences against known allergen databases have consistently found no matches, and panels have rated the risk of allergic reactions as low under normal dietary exposure conditions. However, as noted in EFSA opinions, the risk of allergic reactions by dietary exposure cannot be entirely excluded. Occupational exposure via inhalation (relevant to workers in enzyme manufacturing, not supplement consumers) may carry a distinct sensitization risk not evaluated in these dietary exposure assessments.

8.4 Interaction with Beta-Glucan Health Effects

A functionally important safety consideration specific to glucanase is its potential to degrade intact dietary beta-glucan before the fiber exerts its established health benefits. Beta-glucans have health benefits as dietary fiber, and hence high activity of β-glucanase is not always desirable. Consumers taking glucanase supplements alongside foods specifically chosen for their beta-glucan content (oat products, barley products) should be aware that the enzyme could reduce the molecular weight and viscosity of beta-glucan in the gut, potentially attenuating the fiber's cholesterol-lowering and glycemic benefits that depend on viscosity formation.

8.5 Absence of Relevant Human Interaction Data

No peer-reviewed studies evaluating pharmacokinetic interactions between glucanase supplements and pharmaceutical drugs, or examining glucanase safety specifically in vulnerable human populations (e.g., pregnant women, immunocompromised individuals), were identified in the authoritative literature. Beta-glucanase is sourced primarily from fungi or bacteria that have been used in food and supplements for decades. These strains are selected specifically for their safety and ability to produce high-purity enzymes.

References

Health Conditions

Health conditions that Glucanase may help support.

Digestive Enzyme HealthScientific
Glucanase (beta-glucanase) hydrolyzes beta-glucan polysaccharides found in cereal grains such as oats and barley. It is included in digestive enzyme formulations for plant-based and grain-heavy diets to reduce viscous beta-glucan in the gut and improve nutrient absorption and GI comfort.

Body Systems

Body systems that Glucanase may help support.

No body systems available.